Accelerate to discover

Homepage>Discover>Differentation displacement in acute myeloid leukemia through enhancer activation

Jul 19, 2019

Tycho tells you so much about the quality of your protein. It tells you about presence, purity, concentration,...

Expanding patient tumor samples has never been so easy - Discover AVATAR

Jul 10, 2019

The AVATAR Cell Control System lets you fine-tune oxygen and pressure to cater culture conditions to your cell type of...

Take advantage of 4D mode

Jul 4, 2019

Cutting edgce cardiovascular research demands cutting edge technology. 4D imaging brings together dynamic motion and 3D...

CQ1 confocal quantitative image cytometer: fighting colon cancer with killer cells

Jul 2, 2019

Genetically modified immune cells can successfully destroy colon cancer cells. This has been demonstrated for the first...

Jul 21, 2019

Assessment of angiotensin II-induced mouse models of abdominal aortic aneurysm

Jun 28, 2019

Are you working with high ultrasound imaging and are you interesting in progression/ regression of abdominal aortic...

Bionano introduce new SP blood and cell culture DNA isolation kit

Jun 26, 2019

This Bionano prep SP blood and cell culture DNA isolation kit, can provide ultra-high molecular weight (UHMW) gDNA in...

Breast cancer‐derived exosomes reflect the cell of origin phenotype

Jun 24, 2019

The qNano Gold measures particles using the Tunable Resistive Pulse Sensing (TRPS) principle. TRPS is the most powerful...

Jul 21, 2019

Transcutaneous implantation of valproic acid-encapsulated

Jun 21, 2019

The interest in alternative material systems and delivery methods for treatment of androgenetic alopecia has been...

Show all topics (10)

Differentation displacement in acute myeloid leukemia through enhancer activation

Aug 7, 2018

LSD1 is a flavin adenine dinucleotide (FAD)-dependent homolog of the amine oxidase family and there was recently brought attention to it as a potential therapeutic target. The interest came from an observation of unusually high expression of LSD1 in certain types of poor-prognosis cancers. It was previously thought that LSD1 removes monomethyl and dymethyl histone marks. However, recently it was showed that it interacts with multiple transcripton factor. This raised a possibility of other drugs being used.

New inhibitor ORY-1001 was succesfully tested on LSD1 and blast cell differentioation was observed. The flow cytometric testing on this experiment was done with Novocyte. ORY-1001 disrupts the protein interaction between LSD1 and GFI1.

Scientific paper

Application

Related technologies: Conventional flow cytometry

Get more info